Delivery Order SPE2DB22D2211-SPE2DB24FNUT0

Award Date 6/25/24
Potential Completion Date 6/26/24
Potential Value $1.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Losartan-HCTZ 100-12.5 mg tablets in 90-count packages to the Defense Logistics Agency (DLA). The $2,043.31 firm fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on July 29, 2024, with a completion date of July 30, 2024. The contract has no set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
This federal contract award is for the delivery of Losartan-HCTZ 100-12.5 mg tablets in 90-count bottles. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a firm fixed price of $1,443.67 and a completion date of November 4, 2024. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA, valued at...
This federal contract award is for the delivery of Losartan-HCTZ 100-12.5 mg tablets to the Defense Logistics Agency (DLA). The contract was awarded to AmerisourceBergen Drug Corp's Corporate Office division, a major pharmaceutical distributor, for a fixed price of $19,370.98. The contract has an ultimate completion date of August 27, 2024 and is a delivery order under an Indefinite Delivery Contract (IDC) valued at up to $999,999,999 through December 2025. The IDC is with the DLA Troop...
This federal contract award is for the delivery of Losartan-HCTZ 100-12.5 mg tablets to the Defense Logistics Agency (DLA). The contract was awarded to Amerisourcebergen Drug Corporation's Corporate Office division, a major pharmaceutical distribution company. The contract has a ceiling value of $13,318.06 and a completion date of June 26, 2024. It is a firm-fixed-price delivery order contract, without any set-aside designation. Amerisourcebergen holds a significant Indefinite Delivery...
This federal contract award is for the delivery of Losartan Potassium 100 mg tablets to the Defense Logistics Agency (DLA). The $1,327.22 firm fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. This contract is a delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for...
This federal contract award is for the delivery of Losartan-HCTZ 100-25 mg tablets in 90-count packages to the Defense Logistics Agency (DLA). The contract, valued at $10,362.94, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order with a firm fixed price, and it has no set-aside designation, indicating open competition. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., which holds a...
This federal contract award is for the delivery of Losartan Potassium 25mg tablets in 1000-count bottles to the Defense Logistics Agency (DLA). The $1,754.26 firm-fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider registered in the System for Award Management (SAM.gov). The contract has a completion date of November 8, 2024 and was awarded on November 7, 2024. This delivery order is part of...
This federal contract award is for the delivery of Losartan-HCTZ 100-25 mg tablets in 90-count packages. The contract was awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for a not-to-exceed ceiling value of $2,925.12. The contract is a Delivery Order with a Firm Fixed Price pricing type and a completion date of June 28, 2024. The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with...
This is a federal delivery order contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract, valued at $11,544.06, is for the supply of Losartan-HCTZ 100-12.5 mg tablets in 90-count packages. The contract has a completion date of September 24, 2024 and is a Firm Fixed Price delivery order. Amerisourcebergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to...
This federal contract award is for the delivery of Losartan-HCTZ 100-12.5 mg tablets in 90-count packages. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a ceiling value of $6,664.63 and a period of performance through May 15, 2024. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open...
  • SPE2DB22D2211
    Indefinite Delivery Contract
  • SPE2DB22D2211-SPE2DB24FNUT0
    Delivery Order

This federal contract award is for the delivery of Losartan-HCTZ 100-25 mg tablets in 90-count bottles to the Defense Logistics Agency (DLA). The $1,218.75 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, on June 25, 2024, with an ultimate completion date of June 26, 2024. The order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 between Amerisourcebergen and the DLA, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. This contract does not have a set-aside designation.

Generated 9/24/24, 9:32 AM